Pampeno Christine, Opp Silvana, Hurtado Alicia, Meruelo Daniel
Department of Pathology, NYU Grossman School of Medicine, New York University, New York, NY 10016, USA.
BioNTech, Cambridge, MA 02139, USA.
Int J Mol Sci. 2024 Mar 2;25(5):2925. doi: 10.3390/ijms25052925.
This review article provides a comprehensive overview of a novel Sindbis virus vaccine platform as potential immunotherapy for ovarian cancer patients. Ovarian cancer is the most lethal of all gynecological malignancies. The majority of high-grade serous ovarian cancer (HGSOC) patients are diagnosed with advanced disease. Current treatment options are very aggressive and limited, resulting in tumor recurrences and 50-60% patient mortality within 5 years. The unique properties of armed oncolytic Sindbis virus vectors (SV) in vivo have garnered significant interest in recent years to potently target and treat ovarian cancer. We discuss the molecular biology of Sindbis virus, its mechanisms of action against ovarian cancer cells, preclinical in vivo studies, and future perspectives. The potential of Sindbis virus-based therapies for ovarian cancer treatment holds great promise and warrants further investigation. Investigations using other oncolytic viruses in preclinical studies and clinical trials are also presented.
这篇综述文章全面概述了一种新型辛德毕斯病毒疫苗平台，作为卵巢癌患者潜在的免疫疗法。卵巢癌是所有妇科恶性肿瘤中致死率最高的。大多数高级别浆液性卵巢癌（HGSOC）患者被诊断为晚期疾病。目前的治疗方案非常激进且有限，导致肿瘤复发，5年内患者死亡率达50%-60%。近年来，武装溶瘤辛德毕斯病毒载体（SV）在体内的独特特性引起了人们对有效靶向和治疗卵巢癌的极大兴趣。我们讨论了辛德毕斯病毒的分子生物学、其对卵巢癌细胞的作用机制、临床前体内研究以及未来展望。基于辛德毕斯病毒的疗法在卵巢癌治疗中的潜力前景广阔，值得进一步研究。还介绍了在临床前研究和临床试验中使用其他溶瘤病毒的研究情况。
